The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment (PACE).
 
Jan Alexander Stratmann
Honoraria - Amgen; AstraZeneca/Merck; Boehringer Ingelheim; Bristol-Myers Squibb; Leo Pharma; Novartis; Roche; Takeda
Consulting or Advisory Role - Amgen; Oncopeptides
Research Funding - AstraZeneca/Merck
 
Fabian Acker
No Relationships to Disclose
 
Lukas Aspacher
No Relationships to Disclose
 
Juergen Alt
No Relationships to Disclose
 
Friederike C Althoff
No Relationships to Disclose
 
Sophie Heinzen
No Relationships to Disclose
 
Nicola Gökbuget
No Relationships to Disclose
 
Ina Müller
No Relationships to Disclose
 
Lena Reiser
No Relationships to Disclose
 
Sina Hehn
No Relationships to Disclose
 
Hubert Serve
Honoraria - Gilead Sciences; Novartis; Robert-Bosch-Gesellschaft für Medizinische Forschung mbH
Consulting or Advisory Role - Gilead Sciences; IKP Stuttgart
Patents, Royalties, Other Intellectual Property - COMPANION DIAGNOSTICS FOR LEUKEMIA TREATMENT (Inst); MARKERS FOR RESPONSIVENESS TO AN INHIBITOR OF FLT3; Patent on Oncogene Redirection; Patent on Samhd1 modulation for treating resistance to cancer therapy (Inst)
 
Martin Mänz
No Relationships to Disclose
 
Frauke Meyer
No Relationships to Disclose
 
Martin Sebastian
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; MSD; Novartis; Pfizer/EMD Serono; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi; Takeda
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Pfizer; Takeda